tiprankstipranks
Company Announcements

Corbus Pharmaceuticals’ Promising Cancer Drug Trial Results

Corbus Pharmaceuticals’ Promising Cancer Drug Trial Results

Corbus Pharmaceuticals (CRBP) has issued an update.

Corbus Pharmaceuticals Holdings, Inc. announced promising results from a Phase 1 clinical trial of SYS6002 for treating advanced solid tumors at the ASCO Annual Conference. Conducted in China, the trial showed the drug was well tolerated with mostly low-grade adverse effects and no severe toxicities. Notably, significant anti-tumor responses were observed, with an overall response rate of 44% in metastatic urothelial cancer patients and 43% in cervical cancer patients. The data suggest an encouraging safety and efficacy profile for SYS6002, with ongoing trials to further evaluate its potential as a cancer therapy.

For a thorough assessment of CRBP stock, go to TipRanks’ Stock Analysis page.

Questions or Comments about the article? Write to editor@tipranks.com

Questions or Comments about the article? Write to editor@tipranks.com
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App